Claims for Patent: 10,799,487

Summary for Patent: 10,799,487

Title:	Compositions for the treatment of hypertension
Abstract:	Provided herein are pharmaceutical compositions that are useful for the treatment of hypertension comprising an angiotensin II receptor blocker, a diuretic, and a calcium channel blocker.
Inventor(s):	Anthony RODGERS, Stephen Macmahon
Assignee:	George Institute for Global Health
Application Number:	US16/393,774
Patent Claims:	1. A pharmaceutical composition comprising: (a) telmisartan; (b) indapamide; and (c) amlodipine besylate; wherein a dose of telmisartan is from about 16 mg to about 24 mg, a dose of indapamide is from about 1 mg to about 1.5 mg, and a dose of amlodipine besylate is from about 2 mg to about 3 mg; and wherein the pharmaceutical composition is free of a beta-blocker. 2. The pharmaceutical composition of claim 1, wherein the dose of indapamide is about 1.25 mg. 3. The pharmaceutical composition of claim 1, wherein the dose of amlodipine besylate is about 2.5 mg. 4. The pharmaceutical composition of claim 1, wherein the dose of telmisartan is about 20 mg. 5. The pharmaceutical composition of claim 1, wherein the dose of indapamide is about 1.25 mg and the dose of amlodipine besylate is about 2.5 mg. 6. The pharmaceutical composition of claim 1, wherein the dose of indapamide is about 1.25 mg and the dose of telmisartan is about 20 mg. 7. The pharmaceutical composition of claim 1, wherein the dose of amlodipine besylate is about 2.5 mg and the dose of telmisartan is about 20 mg. 8. The pharmaceutical composition of claim 1, wherein the dose of indapamide is about 1.25 mg, the dose of amlodipine besylate is about 2.5 mg, and the dose of telmisartan is about 20 mg. 9. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is suitable for oral administration. 10. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is in the form of pill, tablet, or capsule. 11. A method of treating hypertension in a subject in need thereof comprising administering to the subject the pharmaceutical composition of claim 1. 12. The method of claim 11, wherein the treatment results in a systolic blood pressure (SBP) of less than about 140 mmHg. 13. The method of claim 11, wherein the treatment results in a reduction of systolic blood pressure (SBP) of about 10 mmHg or greater. 14. The method of claim 11, wherein the treatment results in a diastolic blood pressure (DBP) of less than about 90 mmHg. 15. The method of claim 11, wherein the treatment results in a reduction of diastolic blood pressure (DBP) of about 5 mmHg or greater. 16. The method of claim 11, wherein treatment results in a reduction in systolic blood pressure (SBP) that is greater than the reduction obtained with the full lowest hypertension therapeutic dose of any one of the (a), (b), and (c) in the pharmaceutical composition. 17. The method of any one of claim 11, wherein treatment results in a reduction in diastolic blood pressure (DBP) that is greater than the reduction obtained with the full lowest hypertension therapeutic dose of any one of (a), (b), and (c) in the pharmaceutical composition. 18. The method of claim 11, wherein the treatment results in greater long term tolerability and reduced risk of side effects when compared to treatment with the full lowest hypertension therapeutic dose of any one of (a), (b), and (c) in the pharmaceutical composition. 19. The method of claim 11, wherein the treatment is the initial or first-line treatment of hypertension. 20. The method of claim 11, wherein the subject has not received any previous hypertension therapy prior to treatment.